Journal of Patient-Centered
Research and Reviews
Volume 2

Issue 1

Article 6

1-30-2015

The Clinical Breast Examination: A Useful Screening Tool?
Jennifer Lo

Follow this and additional works at: https://aah.org/jpcrr
Part of the Diagnosis Commons, Neoplasms Commons, Oncology Commons, Public Health Education
and Promotion Commons, and the Women's Health Commons

Recommended Citation
Lo J. The clinical breast examination: a useful screening tool? J Patient Cent Res Rev. 2015;2:34-37. doi:
10.17294/2330-0698.1049

Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the
Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal
focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes,
and the patient experience.

The Clinical Breast Examination: A Useful Screening Tool?
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Abstract	The standardization of the clinical breast examination as a screening tool for breast cancer has been
a topic of controversy. Current recommendations vary significantly from organization to organization
without consensus. There currently does not seem to be sufficient evidence regarding overall survival
benefit of the clinical breast exam. However, as adjunct screening with mammography, it may help find
earlier breast cancers and the up to 5–10% of cancers missed by mammography. The most appropriate
standardized protocol may be that the clinical breast exam can be performed at the discretion of the
provider and patient, with more inclination toward use in women in whom the exam carries greater
sensitivity. (J Patient-Centered Res Rev. 2015;2:34-37.)
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The clinical breast examination is a widely used
practice in both clinical and academic settings. It
has become a standard part of the annual preventive
well-woman examination. How effective the clinical
breast exam is as a screening tool, and the evidence
supporting it, remains ambiguous. Currently, there are
many recommendations regarding use of the clinical
breast exam among various organizations, but no
consensus.

screening mammography ranges from 72% to 80%.3
Mammography reduces the risk of dying from breast
cancer by about 20–35% in women 50–60 years of
age.2,4 Breast cancer usually has no symptoms when
the tumor is small and is easily cured. Mortality
from breast cancer can be directly related to the
stage at diagnosis, which is why there has been so
much attention focused on breast cancer screening
recommendations.

BACKGROUND

About two-thirds of women age 40 or older receive an
annual clinical breast exam screening.5 It is estimated
that 5–10% of breast cancers may be detected by
clinical breast exam alone.5 However, the overall
benefit in survival and outcomes with clinical breast
exams has yet to be proved.

Breast cancer is the most common noncutaneous
form of cancer in women. The 10-year probability
of developing breast cancer increases with age; on
average, the lifetime risk of developing breast cancer
is 1 in 8.1,2 Breast cancer is the second leading cause
of cancer deaths in women, after lung cancer; 88% of
cancer deaths occur in women older than 50 years of
age. Breast cancer deaths have decreased by 28–34%
from 1990 to 2010, a decrease that has been attributed
both to improvements in breast cancer treatment and
early detection.1
It is widely accepted that mammography is the
mainstay in screening modalities for breast cancer,
with digital preferred over film mammography due to
its sensitivity in younger women. The sensitivity of
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CURRENT RECOMMENDATIONS

Many organizations have issued recommendations
regarding providers’ use of the clinical breast exam
as a screening tool for patients at average risk (Table
12,6-10). However, recommendations among these
organizations differ significantly, from insufficient
evidence to recommend screening7,8 to screening
aggressively beginning at age 20 and annually
starting at age 40.9,10 The U.S. Preventive Services
Task Force is in the process of updating its breast
screening guidelines. Its most recent recommendation
from 2009, an update from 2002, states there is
insufficient evidence to recommend for or against
clinical breast exams.6,7 The National Cancer
Institute and the American Academy of Family
Review

Table 1. Summary of current recommendations for
clinical breast examination screening2,6-10
Organization

Recommendation

Canadian Task Force
on Periodic Health
Examination

Age 50–69, annually

National Comprehensive
Cancer Network

Age 25–39, every 1–3 years;
age ≥40, annually

American Academy of
Family Physicians

Insufficient evidence

National Cancer Institute

No specific recommendations

U.S. Preventive Services
Task Force

Insufficient evidence to
recommend for or against

American College
of Obstetricians and
Gynecologists

Age 20–39, every 1–3 years;
age ≥40, annually

American Cancer Society

Age 20–39, every 3 years;
age ≥40, annually

Physicians have no specific recommendations.2,8 The
American Cancer Society and the American College
of Obstetricians and Gynecologists (ACOG) have
the strictest screening guidelines, recommending a
baseline screening at age 20. The ACOG updated its
screening recommendations in 2011.2,9 The National
Comprehensive Cancer Network and the Canadian
Task Force on the Periodic Health Examination each
recommend clinical breast exam every 1–3 years from
age 25 to 39 then annually at age 40–50 and older.10

CURRENT EVIDENCE

A current search for evidence does not yield many
new or recent studies to sway recommendation for or
against screening. There are a few studies that have
compared long-term outcomes using mammography
alone versus mammography in conjunction with
clinical breast exams. Most studies have shown
no difference in outcome. However, there were
more early-stage breast cancers found with dual
screening.11 Perhaps the most referenced study is
the randomized Canadian National Breast Screening
Study-2 (CNBSS-2), which reported 13-year results
in women 50–59 years of age.12 The study compared
two groups of women who were recruited from
January 1980 to March 1985. These women were
followed by record linkage through December 1993
and by active breast cancer registry through June
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1996. One group received annual mammography
with a clinical breast exam, another received clinical
breast exam alone. The results of the study concluded
that yearly mammography with clinical breast exam
detected considerably more lymph node-negative and
small breast cancers but had no impact on mortality
from breast cancer. This study also found that the
sensitivity of the clinical breast exam was 54%, one
of the highest sensitivities reported thus far.
A published study by Bobo et al. looked at breast
cancer screening findings reported to the National
Breast and Cervical Cancer Early Detection Program
from 1995 to 1998.11 This study of low-income
women found that about 5.1% of abnormal clinical
breast exams with normal mammography were later
found by biopsy to be malignant, suggesting that these
cancers may have been missed by mammography
alone. Another 11.2% of cancers detected by clinical
breast exam had missing mammography data. The
average age of women in this study was 52.5 years,
with about 10% of women younger than age 40 and
9% older than age 70. Women with breast symptoms
made up 18.9% of the records examined. Abnormal
results were more common in this group than in
asymptomatic women.
This study also reported a high number of abnormal
clinical breast exams in women under 40 (14.1%),
which the study attributed to artifact as the detection
program does not encourage screening for women
that young.11 Both the inclusion of women with breast
symptoms as well as the high number of abnormal
breast exams in women under 40 may have skewed
the results of this study to reflect a higher number of
detected cancers. This study estimated a sensitivity of
58.8%, specificity of 93.4% and positive predictive
value of 4.3%. Sensitivity decreased with age,
whereas specificity and positive predictive value
increased with age.11
A 2002 study from the Netherlands investigated the
predictors of sensitivity in the clinical breast exam.
The study reported sensitivity of the clinical breast
exam to be, on average, 35%, varying somewhat based
on risk factors.5 The study examined women age 50
years or older and high-risk women age 40–49. Study
participants were invited for a screening visit during
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which a trained nurse performed a clinical breast
exam and a screening mammogram. Investigators
reported that the strongest predictor of detection of
cancer with clinical breast exam was tumor size.
The highest sensitivity was observed in women
50–59 years of age, with sensitivity significantly
lower in women 40–49 years and those 80 years or
older. Sensitivity also was higher among Asian and
white women, women with lower body weight (<135
pounds) and women on hormone replacement therapy
with estrogen and progesterone.

be screened with mammography based on current
recommendations, have yet to be seen. Most studies
have shown no difference in outcome, suggesting
that performing clinical breast exams on women who
are already undergoing mammography prevents no
additional deaths from breast cancer.2,11,12 There is,
however, some evidence that clinical breast exams
as an adjunct screening tool may help detect earlier
cancers and interval cancers. Some studies have
reported that the clinical breast exam may find some
cancers initially missed by mammography.2

A 2005 review article on breast cancer screening by
Elmore et al. reported sensitivities of clinical breast
exams from community practices ranging from 28%
to 36%.4

While clinical breast exam is not without risks,
namely the consequences of false positives resulting
in further testing, the exam in itself is relatively quick,
easy to perform and benign.

One study of interval breast cancers, defined as
breast cancers discovered within 1 year of normal
screening mammography, found that 16% of interval
cancers were found during routine clinical breast
exam performed by clinicians in asymptomatic
women.3 The remainder were found by subsequent
mammograms conducted on women who presented
with a breast concern or complaint. Not surprisingly,
the interval cancers were higher-stage, larger tumors
and had more lymph node positivity than those with
mammography screening-detected cancers. The
factor that most influenced discovery was a patient
having two or more breast concerns; the most often
reported concerns were a breast lump and a personal
and/or family history of breast cancer.3

The bigger picture may involve access to preventive
care providers for any type of screening. One
retrospective study of patients with newly diagnosed
breast cancer reviewed the health care utilization
patterns of patients with early breast cancer versus
locally advanced breast cancer.13 While both groups
had a similar number of contacts with the health
care system, the early breast cancer group attended
primary care visits at higher rates, received higher
rates of breast imaging studies and were three times
more likely to have received a clinical breast exam.

The clinical breast exam itself is a relatively
benign exam. Its potential harms stem from falsepositive results that can lead to consequences
such as overdiagnosis, patient anxiety, pain from
mammography compression and radiation exposure.
It has been reported that after 10 years of screening,
50% of women will have at least one false-positive
mammogram and 20% of women will have one falsepositive clinical breast exam.4

DISCUSSION

There continues to be ambiguous evidence regarding
the use of the clinical breast exam as a screening
tool. Any benefits in survival related to clinical
breast exam, especially in women who are likely to
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Research for breast screening is quite dynamic, and
new evidence emerges frequently. In fact, a 25-year
follow-up study from the CNBSS-2 preliminarily
concluded that annual mammography for those age
40–59 years did not reduce mortality from breast
cancer more than regular physical breast exam.14 It
will be interesting to see if further studies supporting
this finding emerge in the upcoming years, and how
the myriad recommendations may change based on
new findings.

CONCLUSIONS

Currently, it would be reasonable to conclude that
a clinical breast examination may be done at the
discretion of the provider and the patient in women
at average risk. Presence of risk factors such as
family or personal history of breast cancer and breast
complaints as well as characteristics that suggest
increased clinical breast exam sensitivity (e.g. age

Review

50–59 years, low body weight, Asian and Caucasian
ethnicity, hormonal replacement therapy5) would
be practical reasons to perform the clinical breast
exam on a more regular basis. When the decision
is uncertain, pending more evidence regarding the
harm of unnecessary mammography, performing
the clinical breast exam may be more favorable than
refraining from doing so since there is a chance to
detect early-stage breast cancer.
Patient-Friendly Recap
• Clinicians regularly examine their patients’
breasts to check for lumps that may be cancerous.
• The authors report that undergoing this clinical
breast examination has not resulted in any
benefit to overall survival, and it may generate
unnecessary tests.
• However, clinical breast exams can help
detect a small percentage of cancers missed by
mammography, especially in smaller women
50–59 years of age.
• A clinical breast exam may be performed for any
patient if she and her clinician agree, as it may
detect early-stage breast cancer.
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